Immunotherapy plus chemo shows promise in shrinking HPV throat tumors before surgery
NCT ID NCT07290621
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether giving the immunotherapy drug toripalimab along with standard chemotherapy before surgery or radiation can shrink HPV16-positive oropharyngeal (throat) tumors by at least 50%. The study enrolls 30 patients with advanced but localized disease. After the drug combo, patients may have robotic surgery or a reduced-intensity chemoradiation plan based on how well the tumor responded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab (an immunotherapy drug) combined with carboplatin and paclitaxel (chemotherapy drugs)
What this could lead to
If successful, this could lead to a treatment approach that shrinks HPV-related throat cancer tumors significantly before surgery or radiation, potentially allowing for less intense follow-up therapy.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 30 participants, so results may not apply to everyone. The drug combination may cause side effects, and it is not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••